iShares International Small-Cap Equity Factor ETF (ISCF)
Live price chart, market sentiment, and community perspectives for iShares International Small-Cap Equity Factor ETF (AMEX: ISCF).
Live price chart, market sentiment, and community perspectives for iShares International Small-Cap Equity Factor ETF (AMEX: ISCF).
On our desk, we are seeing a fascinating dichotomy with ISCF. While the fund just notched a new 12-month high with a NAV around $43.24 and boasted an exceptional 34.07% return in 2025, our macro team is heavily debating the sustainability of this momentum. Because it is heavily weighted in Japanese and UK equities and benefited immensely from a strong euro, pound, and Aussie dollar last year, any shift in foreign exchange rates could quickly neutralize those gains. Market sentiment is cautiously split, making the current 0.24% expense ratio a point of ongoing debate for long-term allocation.
Watching the price action and flow data on ISCF, the short interest update revealing a significant drop aligns with the ETF setting new 12-month highs over the summer of 2026. However, looking under the hood at its multifactor screening methodology—which targets value, quality, momentum, and low volatility across roughly 1,097 developed-world small-caps—we notice a persistent structural risk. Despite its banner 2025, its longer-term annualized metrics over March 2023 to November 2025 show it trailing broad market heavyweights like IVV and SPDW, reminding risk managers that international small-caps carry distinct cyclical headwinds.
When evaluating smart beta strategies like ISCF for client portfolios, our quantitative protocols require looking closely at how the Process and People pillars interact with factor timing. ISCF tracks an index selecting international small-caps via value, quality, momentum, and low volatility factors, carrying a 30-day SEC yield of 2.27% and a 12-month trailing yield of 3.44% as of mid-2026. Analysts evaluating quantitative readiness must weigh whether its 4-star Morningstar rating and Morningstar Medalist status justify tactical overweighting against its historical pattern of lagging US large-cap blend alternatives during broader market corrections.
Explore plasma cleansing, somatic organ swaps, and BCI.